Cargando…

Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs

In this study, the mechanism of the anticancer effect through which cucurbitacin D (CuD) can overcome gefitinib resistance in NSCLC was investigated. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide assay, and cell migration and growth were observed by woun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Se Hyang, Ku, Jin Mo, Lim, Ye Seul, Lee, Seo Yeon, Kim, Ji Hye, Cheon, Chunhoo, Ko, Seong-Gyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041627/ https://www.ncbi.nlm.nih.gov/pubmed/32133284 http://dx.doi.org/10.3389/fonc.2020.00062

Ejemplares similares

Cucurbitacin D Induces G2/M Phase Arrest and Apoptosis via the ROS/p38 Pathway in Capan-1 Pancreatic Cancer Cell Line
por: Kim, Myeong-Sun, et al.
Publicado: (2020)

Personalized post-surgical care?—possible strategies for NSCLCs with EGFR mutation
por: Suda, Kenichi
Publicado: (2020)

Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells
por: Ku, Jin Mo, et al.
Publicado: (2015)

Gardenia jasminoides Enhances CDDP-Induced Apoptosis of Glioblastoma Cells via AKT/mTOR Pathway While Protecting Death of Astrocytes
por: Kim, Hyo In, et al.
Publicado: (2020)

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
por: He, Peng, et al.
Publicado: (2013)

Phase I study to evaluate the maximum tolerated dose of the combination of SH003 and docetaxel in patients with solid cancer: A study protocol
por: Cheon, Chunhoo, et al.
Publicado: (2020)

A Phase I Study to Evaluate the Safety of the Herbal Medicine SH003 in Patients With Solid Cancer
por: Cheon, Chunhoo, et al.
Publicado: (2020)

Synergistic effects of natural products in combination with anticancer agents in prostate cancer: A scoping review
por: Cheon, Chunhoo, et al.
Publicado: (2022)

Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study
por: Gu, Linping, et al.
Publicado: (2022)

SH003 reverses drug resistance by blocking signal transducer and activator of transcription 3 (STAT3) signaling in breast cancer cells
por: Seo, Hye-Sook, et al.
Publicado: (2017)

SH003 activates autophagic cell death by activating ATF4 and inhibiting G9a under hypoxia in gastric cancer cells
por: Kim, Tae Woo, et al.
Publicado: (2020)

Oncogenic miR-9 is a target of erlotinib in NSCLCs
por: Chen, Xi, et al.
Publicado: (2015)

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs
por: Lypova, Nadiia, et al.
Publicado: (2021)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer
por: Liu, Pengfei, et al.
Publicado: (2019)

Traditional Herbal Formula Taeeumjowi-Tang (TJ001) Inhibits p53-Mutant Prostate Cancer Cells Growth by Activating AMPK-Dependent Pathway
por: Kang, Sooyeon, et al.
Publicado: (2019)

hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours
por: Nutt, J E, et al.
Publicado: (2007)

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
por: Pan, Yong-hong, et al.
Publicado: (2018)

Trans‐3,5,4´‐trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl‐2 pathway by upregulation of miR‐345 and miR‐498
por: Lu, Min, et al.
Publicado: (2019)

The prevention of 2,4-dinitrochlorobenzene-induced inflammation in atopic dermatitis-like skin lesions in BALB/c mice by Jawoongo
por: Ku, Jin Mo, et al.
Publicado: (2018)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Implementing accountable care organizations with integrative medicine in Korean health care system
por: Youn, Bo-Young, et al.
Publicado: (2021)

Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis
por: Lan, Bo, et al.
Publicado: (2022)

TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non–small‐cell lung cancer
por: Shuai, Shuai, et al.
Publicado: (2021)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
por: Capalbo, Carlo, et al.
Publicado: (2019)

EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation
por: Yao, Wenfang, et al.
Publicado: (2012)

Gardenia Jasminoides Ameliorates Antibiotic-Associated Aggravation of DNCB-Induced Atopic Dermatitis by Restoring the Intestinal Microbiome Profile
por: Kim, Hyo In, et al.
Publicado: (2021)

Global Trends of Nutrition in Cancer Research: A Bibliometric and Visualized Analysis Study over the Past 10 Years
por: Youn, Bo-Young, et al.
Publicado: (2022)

Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation
por: Jiang, Yuhong, et al.
Publicado: (2021)

Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy
por: Liu, Yuhong, et al.
Publicado: (2022)

Genetic variations in EGF and EGFR and glioblastoma outcome
por: Sjöström, Sara, et al.
Publicado: (2010)

Apigenin overcomes drug resistance by blocking the signal transducer and activator of transcription 3 signaling in breast cancer cells
por: Seo, Hye-Sook, et al.
Publicado: (2017)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations
por: Choi, Seul-Ki, et al.
Publicado: (2022)

TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway
por: Oh, Se Jin, et al.
Publicado: (2023)

Kaempferol induces autophagic cell death via IRE1-JNK-CHOP pathway and inhibition of G9a in gastric cancer cells
por: Kim, Tae Woo, et al.
Publicado: (2018)

Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance
por: Nishimura, Yukio
Publicado: (2018)

Cucurbitacins: elucidation of their interactions with the cytoskeleton
por: Wang, Xiaojuan, et al.
Publicado: (2017)

Pharmacokinetics and Biological Activity of Cucurbitacins
por: Delgado-Tiburcio, Eugenia Elisa, et al.
Publicado: (2022)

Critical enzymes for biosynthesis of cucurbitacin derivatives in watermelon and their biological significance
por: Kim, Young-Cheon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r78424ot716es8hs4bf4scoq4f